Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
- Conditions
- Covid19SARS-CoV InfectionCoagulopathyPneumonia, Viral
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Massimo Girardis
- Target Recruit Count
- 210
- Registration Number
- NCT04528888
- Locations
- 🇮🇹
ICU- University Hospital Modena, Modena, Italy
Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
- Conditions
- Sars-CoV2
- Interventions
- Device: Ultrasound of the lower limbs
- Locations
- 🇫🇷
Centre Hospitalier de Roanne, Roanne, France
🇫🇷Clinique Mutualiste, Saint-Étienne, France
🇫🇷CHU de Saint-Etienne, Saint-Étienne, France
FREEDOM COVID-19 Anticoagulation Strategy
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Valentin Fuster
- Target Recruit Count
- 3460
- Registration Number
- NCT04512079
- Locations
- 🇨🇴
Centro Médico Imbanaco, Cali, Colombia
🇨🇴Clínica Shaio, Bogotá, Colombia
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
- Conditions
- Covid19PneumoniaCoagulation DisorderPulmonary Embolism
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Hospital Regional de Alta especialidad de Ixtapaluca
- Target Recruit Count
- 130
- Registration Number
- NCT04508439
- Locations
- 🇲🇽
Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico City, Ixtapaluca, Mexico
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 82
- Registration Number
- NCT04504318
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 219
- Registration Number
- NCT04492254
- Locations
- 🇦🇺
Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne, Australia
🇧🇪Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat, Belgium
🇿🇦Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg, South Africa
Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial
- Conditions
- SARS-CoV-2 Infection (COVID-19)
- Interventions
- Drug: Nirmatrelvir-RitonavirBiological: (Arm Never Opened) Hyperimmune globulin
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Melbourne
- Target Recruit Count
- 2200
- Registration Number
- NCT04483960
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺Western Health, St Albans, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 100
- Registration Number
- NCT04462003
- Locations
- 🇪🇬
Faculty of Medicine,Beni-Suef University, Banī Suwayf, Beni-Suef, Egypt
Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 301
- Registration Number
- NCT04427098
- Locations
- 🇮🇹
Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy
🇮🇹Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy
🇮🇹Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
- Conditions
- COVID-19Arterial ThrombosisVenous Thromboembolism
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- The TIMI Study Group
- Target Recruit Count
- 390
- Registration Number
- NCT04409834
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.